Blocking myristoylation of Src inhibits its kinase activity and suppresses prostate cancer progression

Sungjin Kim, Omar Awad Alsaidan, Octavia Goodwin, Qianjin Li, Essilvo Sulejmani, Zhen Han, Aiping Bai, Thomas Albers, Zanna Beharry, Y. George Zheng, James S. Norris, Zdzislaw M. Szulc, Alicja Bielawska, Iryna Oleksandrivna Lebedyeva, Scott D. Pegan, Houjian Cai

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Protein N-myristoylation enables localization to membranes and helps maintain protein conformation and function. N-myristoyltransferases (NMT) catalyze co- or posttranslational myristoylation of Src family kinases and other oncogenic proteins, thereby regulating their function. In this study, we provide genetic and pharmacologic evidence that inhibiting the N-myristoyltransferase NMT1 suppresses cell-cycle progression, proliferation, and malignant growth of prostate cancer cells. Loss of myristoylation abolished the tumorigenic potential of Src and its synergy with androgen receptor in mediating tumor invasion. We identified the myristoyl-CoA analogue B13 as a small-molecule inhibitor of NMT1 enzymatic activity. B13 exposure blocked Src myristoylation and Src localization to the cytoplasmic membrane, attenuating Src-mediated oncogenic signaling. B13 exerted its anti-invasive and antitumor effects against prostate cancer cells, with minimal toxic side-effects in vivo. Structural optimization based on structure–activity relationships enabled the chemical synthesis of LCL204, with enhanced inhibitory potency against NMT1. Collectively, our results offer a preclinical proof of concept for the use of protein myristoylation inhibitors as a strategy to block prostate cancer progression.

Original languageEnglish (US)
Pages (from-to)6950-6952
Number of pages3
JournalCancer Research
Volume77
Issue number24
DOIs
StatePublished - Dec 15 2017

Fingerprint

Prostatic Neoplasms
Phosphotransferases
Protein Conformation
Proteins
src-Family Kinases
Poisons
Androgen Receptors
Cell Cycle
Cell Membrane
Membranes
Growth
Neoplasms
glycylpeptide N-tetradecanoyltransferase
S-tetradecanoyl-coenzyme A

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kim, S., Alsaidan, O. A., Goodwin, O., Li, Q., Sulejmani, E., Han, Z., ... Cai, H. (2017). Blocking myristoylation of Src inhibits its kinase activity and suppresses prostate cancer progression. Cancer Research, 77(24), 6950-6952. https://doi.org/10.1158/0008-5472.CAN-17-0981

Blocking myristoylation of Src inhibits its kinase activity and suppresses prostate cancer progression. / Kim, Sungjin; Alsaidan, Omar Awad; Goodwin, Octavia; Li, Qianjin; Sulejmani, Essilvo; Han, Zhen; Bai, Aiping; Albers, Thomas; Beharry, Zanna; Zheng, Y. George; Norris, James S.; Szulc, Zdzislaw M.; Bielawska, Alicja; Lebedyeva, Iryna Oleksandrivna; Pegan, Scott D.; Cai, Houjian.

In: Cancer Research, Vol. 77, No. 24, 15.12.2017, p. 6950-6952.

Research output: Contribution to journalArticle

Kim, S, Alsaidan, OA, Goodwin, O, Li, Q, Sulejmani, E, Han, Z, Bai, A, Albers, T, Beharry, Z, Zheng, YG, Norris, JS, Szulc, ZM, Bielawska, A, Lebedyeva, IO, Pegan, SD & Cai, H 2017, 'Blocking myristoylation of Src inhibits its kinase activity and suppresses prostate cancer progression', Cancer Research, vol. 77, no. 24, pp. 6950-6952. https://doi.org/10.1158/0008-5472.CAN-17-0981
Kim, Sungjin ; Alsaidan, Omar Awad ; Goodwin, Octavia ; Li, Qianjin ; Sulejmani, Essilvo ; Han, Zhen ; Bai, Aiping ; Albers, Thomas ; Beharry, Zanna ; Zheng, Y. George ; Norris, James S. ; Szulc, Zdzislaw M. ; Bielawska, Alicja ; Lebedyeva, Iryna Oleksandrivna ; Pegan, Scott D. ; Cai, Houjian. / Blocking myristoylation of Src inhibits its kinase activity and suppresses prostate cancer progression. In: Cancer Research. 2017 ; Vol. 77, No. 24. pp. 6950-6952.
@article{d5d493ca86dc4c128db0948391a60ee5,
title = "Blocking myristoylation of Src inhibits its kinase activity and suppresses prostate cancer progression",
abstract = "Protein N-myristoylation enables localization to membranes and helps maintain protein conformation and function. N-myristoyltransferases (NMT) catalyze co- or posttranslational myristoylation of Src family kinases and other oncogenic proteins, thereby regulating their function. In this study, we provide genetic and pharmacologic evidence that inhibiting the N-myristoyltransferase NMT1 suppresses cell-cycle progression, proliferation, and malignant growth of prostate cancer cells. Loss of myristoylation abolished the tumorigenic potential of Src and its synergy with androgen receptor in mediating tumor invasion. We identified the myristoyl-CoA analogue B13 as a small-molecule inhibitor of NMT1 enzymatic activity. B13 exposure blocked Src myristoylation and Src localization to the cytoplasmic membrane, attenuating Src-mediated oncogenic signaling. B13 exerted its anti-invasive and antitumor effects against prostate cancer cells, with minimal toxic side-effects in vivo. Structural optimization based on structure–activity relationships enabled the chemical synthesis of LCL204, with enhanced inhibitory potency against NMT1. Collectively, our results offer a preclinical proof of concept for the use of protein myristoylation inhibitors as a strategy to block prostate cancer progression.",
author = "Sungjin Kim and Alsaidan, {Omar Awad} and Octavia Goodwin and Qianjin Li and Essilvo Sulejmani and Zhen Han and Aiping Bai and Thomas Albers and Zanna Beharry and Zheng, {Y. George} and Norris, {James S.} and Szulc, {Zdzislaw M.} and Alicja Bielawska and Lebedyeva, {Iryna Oleksandrivna} and Pegan, {Scott D.} and Houjian Cai",
year = "2017",
month = "12",
day = "15",
doi = "10.1158/0008-5472.CAN-17-0981",
language = "English (US)",
volume = "77",
pages = "6950--6952",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Blocking myristoylation of Src inhibits its kinase activity and suppresses prostate cancer progression

AU - Kim, Sungjin

AU - Alsaidan, Omar Awad

AU - Goodwin, Octavia

AU - Li, Qianjin

AU - Sulejmani, Essilvo

AU - Han, Zhen

AU - Bai, Aiping

AU - Albers, Thomas

AU - Beharry, Zanna

AU - Zheng, Y. George

AU - Norris, James S.

AU - Szulc, Zdzislaw M.

AU - Bielawska, Alicja

AU - Lebedyeva, Iryna Oleksandrivna

AU - Pegan, Scott D.

AU - Cai, Houjian

PY - 2017/12/15

Y1 - 2017/12/15

N2 - Protein N-myristoylation enables localization to membranes and helps maintain protein conformation and function. N-myristoyltransferases (NMT) catalyze co- or posttranslational myristoylation of Src family kinases and other oncogenic proteins, thereby regulating their function. In this study, we provide genetic and pharmacologic evidence that inhibiting the N-myristoyltransferase NMT1 suppresses cell-cycle progression, proliferation, and malignant growth of prostate cancer cells. Loss of myristoylation abolished the tumorigenic potential of Src and its synergy with androgen receptor in mediating tumor invasion. We identified the myristoyl-CoA analogue B13 as a small-molecule inhibitor of NMT1 enzymatic activity. B13 exposure blocked Src myristoylation and Src localization to the cytoplasmic membrane, attenuating Src-mediated oncogenic signaling. B13 exerted its anti-invasive and antitumor effects against prostate cancer cells, with minimal toxic side-effects in vivo. Structural optimization based on structure–activity relationships enabled the chemical synthesis of LCL204, with enhanced inhibitory potency against NMT1. Collectively, our results offer a preclinical proof of concept for the use of protein myristoylation inhibitors as a strategy to block prostate cancer progression.

AB - Protein N-myristoylation enables localization to membranes and helps maintain protein conformation and function. N-myristoyltransferases (NMT) catalyze co- or posttranslational myristoylation of Src family kinases and other oncogenic proteins, thereby regulating their function. In this study, we provide genetic and pharmacologic evidence that inhibiting the N-myristoyltransferase NMT1 suppresses cell-cycle progression, proliferation, and malignant growth of prostate cancer cells. Loss of myristoylation abolished the tumorigenic potential of Src and its synergy with androgen receptor in mediating tumor invasion. We identified the myristoyl-CoA analogue B13 as a small-molecule inhibitor of NMT1 enzymatic activity. B13 exposure blocked Src myristoylation and Src localization to the cytoplasmic membrane, attenuating Src-mediated oncogenic signaling. B13 exerted its anti-invasive and antitumor effects against prostate cancer cells, with minimal toxic side-effects in vivo. Structural optimization based on structure–activity relationships enabled the chemical synthesis of LCL204, with enhanced inhibitory potency against NMT1. Collectively, our results offer a preclinical proof of concept for the use of protein myristoylation inhibitors as a strategy to block prostate cancer progression.

UR - http://www.scopus.com/inward/record.url?scp=85038598798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038598798&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-17-0981

DO - 10.1158/0008-5472.CAN-17-0981

M3 - Article

C2 - 29038344

AN - SCOPUS:85038598798

VL - 77

SP - 6950

EP - 6952

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 24

ER -